Dentsply Sirona has announced that Daniel Scavilla, a current member of its Board of Directors, will take on the role of President and Chief Executive Officer beginning August 1, 2025. He will succeed Simon Campion, who is set to depart the company on July 31, 2025.
Scavilla brings over 30 years of experience in the medical technology and pharmaceutical sectors. Most recently, he served as President and CEO of Globus Medical, where he led the acquisition and integration of NuVasive. Before that, he spent nearly three decades at Johnson & Johnson in various financial and operational leadership roles. He joined Dentsply Sirona’s Board in February 2025.
Gregory T. Lucier, Chairman of the Board, stated, “Dan’s appointment as CEO underscores the Board’s strong and unwavering commitment to delivering enhanced value to shareholders and positioning Dentsply Sirona for future success. Dan is a seasoned healthcare veteran, and we’re confident that his three decades of executive leadership experience and disciplined focus on commercial growth, product innovation, and financial and operational excellence make him well-suited to lead the company into its next chapter. There is significant untapped opportunity across the dental market, and we believe that Dan is the right leader to help accelerate the company’s business transformation, reposition Dentsply Sirona as an industry leader, and deliver long-term value creation.”
Reflecting on his new role, Scavilla commented, “Dentsply Sirona is a company that I have admired for its trusted brands, and since joining the Board in February, I have gained an even deeper appreciation for the enormous potential of our business, people, and products. The Board and I are aligned in our belief that, while our ongoing transformation is yielding results, there is more we can do to drive improved commercial, operational, and financial performance across the organization. As I step into the CEO role, I look forward to working with the team to continue the company’s transformation and drive sustained profitable growth and enhance value for all stakeholders.”
Lucier also acknowledged the contributions of the outgoing CEO, saying, “On behalf of the Board of Directors, I want to thank Simon for his contributions to our company, laying a strong foundation for continued success, while upholding high integrity and transparency. We appreciate his commitment to Dentsply Sirona and wish him all the best in his future endeavors.”
“It has been a privilege to serve as CEO over the past three years,” Campion said. “While we have had to address a number of challenges, Dentsply Sirona now has a strong foundation in place, and I fully expect the company will reach new heights under Dan’s leadership.”
As part of the transition, Campion has stepped down from the Board. Scavilla will remain on the Board but will no longer serve on its Audit and Finance Committee.
As CEO of Globus Medical, Scavilla led the acquisition of NuVasive in an all-stock transaction valued at $3 billion. The merger positioned the combined entity as the second-largest spine technology company globally. During his time at Globus Medical, he held several leadership roles, including Chief Financial Officer, Executive Vice President, Chief Commercial Officer, and President of the Trauma division. Prior to that, he spent 28 years at Johnson & Johnson, where he worked in various business areas, including serving as CFO and Worldwide VP of Finance for Advanced Sterilization Products. He holds a BS in Finance and Organizational Behavior from LaSalle University and an MBA in International Management from Temple University.
Figures and Images
Daniel Scavilla
